 ProchymalTM MSCs will be infused into patients with moderate-to-severe Crohns disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohns disease symptoms. Patients will receive high or low dose. Study is open label. 